Description
Angioedema is a common but potentially lifethreatening adverse drug reaction associated with Angiotensin Converting Enzyme (ACE) inhibitor therapy. The exact mechanism of ACE inhibitor induced angioedema remains unknown but an increase in bradykinin (BK) levels has been postulated. Angiotensin receptor blockers (ARBs) do not inhibit ACE and therefore do not inhibit breakdown of BK. However angioedema with ARB therapy has now been clearly shown. This risk appears increased in those who have had a previous documented angioedema on an ACE inhibitor. Angiotensin receptor blockers should therefore be prescribed with caution in patients with a past history of ACE inhibitor induced angioedema.
